Purpose: Trastuzumab-pertuzumab (HP) plus taxane is a current standard first-line therapy for recurrent or metastatic human epidermal growth factor 2 (HER2)+ breast cancer (BC). We investigated noninferiority of eribulin to a taxane when combined with dual HER2 blockade as first-line systemic treatment for locally advanced/metastatic HER2+ BC.
Methods: In the phase III EMERALD trial (target sample size, 480; ClinicalTrials.
Background: Pseudarthrosis is a major complication after posterior lumbar interbody fusion (PLIF) and transforaminal interbody fusion (TLIF), and its risk factors need to be identified. This study aimed to investigate the relationship between the number of remaining teeth (NRT) and pseudarthrosis.
Methods: NRT, preoperative bone density of the proximal femur (percentages of young adult mean; % YAM), and preoperative procollagen type 1 N-terminal propeptide (P1NP) (μg/L) were retrospectively investigated in 63 patients (24 male and 39 female, mean age: 71.
Metastasis in patients with oral squamous cell carcinoma has been associated with a poor prognosis. However, sensitive and reliable tests for monitoring their occurrence are unavailable, with the exception of PET-CT. Circulating tumor cells and cell-free DNA have emerged as promising biomarkers for determining treatment efficacy and as prognostic predictors in solid tumors such as breast cancer and colorectal cancer.
View Article and Find Full Text PDFThe autologous pericardial aortic valve repair technique developed by Ozaki et al., using glutaraldehyde-treated autologous pericardium, has demonstrated superior durability to bioprosthetic valves. However, this technique has certain limitations, including excessive cusp height and cusp fluttering due to leaflet redunduncy.
View Article and Find Full Text PDF